With $308M in cash, Duke spinout Aerie readying for commercialization

With roughly $308 million in cash and equivalents, Duke University spinout Aerie Pharmaceuticals (Nasdaq: AERI) is readying for commercialization, the company stated along with its second quarter financial results Tuesday. On the company's earnings call, Vicente Anido Jr., chairman and CEO of Aerie, stated that all of the company's programs – which consist of eye drop products for the treatment of glaucoma – are on track. A new drug application for Rhopressa has been accepted by the U.S. Food…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news